The Japanese group pays $315m to co-develop an asset Vir got from a low-cost Sanofi deal.
ApexOnco Front Page
Recent articles
Solstice Oncology acquires porustobart from Harbour Biomed.
SGN-CEACAM5C carries the same antibody as the discontinued tusamitamab ravtansine.
An actinium-based backup and Werner helicase inhibitor are notable absences.
But the Astra/Daiichi ADC stumbles in lung cancer.
First-in-human listings bring a bispecific and yet another in vivo Car-T.
Cafelkibart’s entry into phase 3 is of note to Coherus.
The company quietly deprioritises AlphaMedix.
